Biometry

What Biometry does

Biometry Inc. (dba myBiometry) is a US-based health technology company developing diagnostic and remote monitoring tools for patients with chronic respiratory conditions, primarily asthma and COPD. Its core product, fenoTRACK, is a pre-commercial medical device system comprising a portable handheld sensor, single-use test strips, and a companion mobile application that measures fractional exhaled nitric oxide (FeNO) in exhaled breath as a biomarker for type 2 airway inflammation. Device readings, combined with clinical and environmental risk factors collected through the app, are fed into a proprietary "Prediction Engine" intended to generate personalized risk models that anticipate asthma and COPD exacerbations up to 20 days in advance. The company is pursuing FDA regulatory clearance for fenoTRACK and has not yet commercialized the product.

The business model is a combination of hardware sales (the fenoTRACK device) and consumables (test strips), with potential subscription or service revenue for continuous monitoring and clinical decision support delivered through the app. Go-to-market is structured as enterprise field sales targeting four distinct segments: patients (direct, at-home monitoring), clinicians (pulmonologists, allergists, primary care), healthcare payers and insurers (cost reduction via early intervention), and pharmaceutical companies (companion diagnostics and clinical trial support). The company is headquartered in Lowell, Massachusetts with an operational office in Fishers, Indiana.

Biometry is venture-backed and pre-revenue. To date it has raised approximately $8.99 million in disclosed equity financing, including a $5 million oversubscribed Seed round led by Dexcom Ventures in November 2024 with participation from CareSource Indiana, Elevate Ventures, and New York Angels, plus a subsequent ~$3.99 million SEC Form D exempt offering filed in December 2025. The company has also received non-dilutive capital from the Massachusetts Manufacturing Innovation Initiative ($626,000, July 2024), MassChallenge accelerators, and selection into the 2026 Blue Cross Blue Shield of Massachusetts / MassChallenge Health Equity Business Accelerator. Leadership includes alumni of Quanterix, Roche/Ventana, Novartis, QIAGEN, Becton Dickinson, and TheraSense, supported by clinical advisors including Professor Ian Pavord of Oxford, the second-highest cited asthma researcher worldwide.

Name

Biometry

Legal name

BIOMETRY Inc.

Website

https://mybiometry.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

11–50 employees

Short description

Biometry (myBiometry) is a US-based health technology company developing fenoTRACK, a pre-commercial at-home FeNO breath test device with companion app and predictive engine, targeting asthma and COPD patients, clinicians, payers, and pharmaceutical companies.

Ownership category

akta.pro rank

Product category

Respiratory Diagnostic Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Surgical & Medical Instruments & Apparatus (3841), Laboratory Analytical Instruments (3826)

akta.pro primary industry

Blood Oxygen & Respiratory Monitoring (Pulse Oximetry, Capnography, Spirometry) (HLAHACAD)

akta.pro secondary industries

Pulmonary Function Testing (PFT) & Spirometry Equipment (HLAHAGAH), COPD & Chronic Bronchitis Management (HLAKANAE), Asthma & Airway Disease Specialty Care (HLAKAAAC), Respiratory Monitoring & Oximetry (Capnography, Pulse Oximeters, Respiratory Rate) (HLAHAGAI)

Keywords

• Respiratory diagnostic devices
• FeNO breath analysis
• Asthma remote monitoring
• COPD exacerbation prediction
• Connected health sensors

Headquarters

HQ city

Boston

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Others

Revenue model

1. fenoTRACK Device and Test Strips: The company is developing a medical device (fenoTRACK) consisting of a portable device, test strips, and mobile app. Revenue will likely come from hardware sales (device) combined with consumable sales (test strips) for ongoing monitoring. Products are currently under development and have not yet been cleared by the FDA.
2. Remote Monitoring Services: Potential subscription or service model for continuous monitoring, data analytics, and clinical decision support delivered through the app platform to patients, clinicians, and healthcare payers.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Biometry develops fenoTRACK, a portable, non-invasive breath diagnostic system comprising a handheld sensor device, single-use test strips, and a companion mobile app. The device measures fractional exhaled nitric oxide (FeNO) to quantify type 2 airway inflammation in asthma and COPD patients, and feeds that data into a prediction engine that builds personalized risk models to predict exacerbations up to 20 days in advance. The product is currently under development and pending FDA regulatory clearance.

Product overview

myBiometry offers a unified product ecosystem centered on fenoTRACK — a medical device system comprising a handheld sensor device, single-use test strips, and a companion mobile application. The system enables at-home measurement of fractional exhaled nitric oxide (FeNO) as a biomarker for airway inflammation. The companion app collects clinical and environmental risk factors, which feed into the proprietary myBiometry Prediction Engine that generates personalized, predictive risk models for each patient. The platform delivers actionable insights and guideline-based self-management education to empower patients to prevent asthma and COPD attacks. The product is currently under development and pending FDA regulatory clearance.

Differentiator

Problem solved

Functional benefit

Brands

• fenoTRACK: Portable, non-invasive breath test device that measures type 2 airway inflammation via fractional exhaled nitric oxide (FeNO) for asthma and COPD patients

Products and services

• fenoTRACK A portable, non-invasive breath diagnostic system for asthma and COPD patients that measures fractional exhaled nitric oxide (FeNO) via a patented handheld sensor and disposable test strips to detect type 2 airway inflammation, combined with a mobile app that aggregates clinical and environmental risk factors into a prediction engine for early detection of exacerbations up to 20 days in advance.

Quantifiable outcome

• Early detection up to 20 days in advance
• +4 more outcomes

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature4 records

Partnerships

One partnership is on record.

• MassChallenge / Blue Cross Blue Shield of MassachusettscoreStrategic or Co-development Partner · 12 February 2026myBiometry was selected as one of five startups for the 2026 Health Equity Business Accelerator program in Boston. The program provides each startup with a $50,000 grant and three months of tailored support to address health inequities. Blue Cross Blue Shield of Massachusetts and MassChallenge jointly run this accelerator.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Others

• AstraZeneca: AstraZeneca markets Dupixent (with Sanofi/Regeneron) and other Type 2 inflammation biologics that target the same patient population Biometry serves. Represents a potential pharma partner for companion diagnostics and clinical trial stratification using fenoTRACK.
• Quanterix: Quanterix is an ultra-sensitive biomarker detection platform used in respiratory and immunology research. Biometry's CPO previously served as Sr. Director of Engineering at Quanterix, and the companies share a diagnostics/customer base in respiratory biomarker research.

Direct peers

• Bedfont Scientific: Bedfont manufactures the NObreath FeNO monitor, a direct competitor in point-of-care and clinical FeNO measurement. Comparable in target customer (pulmonologists, allergists, PCPs) and clinical use case.
• Bosch Healthcare Solutions: Bosch's Vivatmo pro and Vivatmo me FeNO devices compete directly in the FeNO monitoring category. Backed by Bosch's industrial scale, they represent a well-resourced incumbent in the same product category.
• NIOX Group: NIOX (formerly Circassia/Aerocrine) is the global leader in FeNO measurement with NIOX VERO and NIOX MINO devices used in pulmonary clinics. It is the most direct competitor to Biometry's fenoTRACK, though Biometry differentiates on at-home use and predictive analytics.

Emerging players

• FindAir: FindAir offers a smart inhaler add-on and respiratory health app for asthma and COPD patients. Comparable in targeting at-home digital respiratory monitoring, though focused on inhaler-based rather than FeNO biomarker data.
• Propeller Health (ResMed): Propeller (acquired by ResMed) provides digital respiratory health tools, including smart inhaler sensors and adherence/predictive analytics for asthma and COPD. Overlaps with Biometry on the digital monitoring and prediction layer but uses a different sensor modality.
• Adherium: Adherium develops smart inhaler sensors and a digital respiratory platform focused on medication adherence and remote monitoring for asthma and COPD. Comparable target patient population and digital health model.

Broad incumbents

• Philips Respironics: Philips Respironics is a major incumbent in respiratory care, offering nebulizers, oxygen therapy, ventilators, and sleep diagnostics. Touches the same patient population as Biometry through broader respiratory care channels.
• ResMed: ResMed is a global leader in respiratory and sleep medicine devices and the parent of Propeller Health. Provides broad respiratory care infrastructure across sleep apnea, COPD, and asthma — overlapping with Biometry in COPD management and remote monitoring.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/mybiometry
• LinkedInlinkedin.com/company/mybiometry

Revenue estimate

Valuation estimate

Number of profiles

Profiles14 records

Funding overview

Funding rounds8 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Biometry